Montreal, QC – August 12, 2026 – MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries, announced today that its Continuous Perfusion Sensing Technology (CPST) Platform has received market authorization in Australia and has been added to the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA), under ARTG Identifier 529808.
The Australian authorization marks a key milestone in MY01’s growth trajectory, unlocking one of the world’s most respected healthcare markets and giving hospitals and surgical teams across the country direct access to continuous, real-time monitoring of limb perfusion technology that is rapidly gaining recognition as an emerging standard of care for patients at risk of compartment syndrome.
“We’re excited about the growing global demand for our CPST Platform. Entering Australia is another important step in our mission to standardize this technology, ensuring that patients and surgeons everywhere can access the highest quality of care,” said Andrew Morris, Chief Commercial Officer at MY01.
With this authorization, Australia becomes MY01’s fourth major market, marking a rapid and compounding expansion that brings the CPST Platform to trauma and orthopedic teams across the globe. Each new market reinforces a crucial trend: continuous monitoring of perfusion pressure at the bedside, in conjunction with clinical assessment, is becoming increasingly essential for diagnosing and managing compartment syndrome.
About MY01 Inc.
Founded in 2019 and based in Montreal, MY01 envisions a world where every disease is quantifiable, enabling precise, personalized care for all patients. At MY01, our Continuous Perfusion Sensing Technology (CPST) Platform has the ability to transform trauma programs by translating complex biological signs into dynamic, actionable, real-time data to inform better decision-making, thereby reducing variation in care and delivering better outcomes, allowing hospitals to allocate resources as efficiently as possible. MY01 is commercial in the United States, Canada, select European markets, and now Australia